Serina Therapeutics, Inc. (SER): debt financing — AgeX Therapeutics draws $500,000 under Secured Convertible Note with Juvenescence Limited

Serina Therapeutics, Inc.

Drew $500,000 on Oct 3, 2023 from existing Amended Secured Convertible Note with Juvenescence Limited.
Repayment of principal due February 14, 2024; terms unchanged from prior filings.
Material terms previously detailed in May 2023 10-Q and June/August 2023 8-Ks.

item 2.03 item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Serina Therapeutics, Inc. incurred loan of $500,000 with Juvenescence Limited maturing February 14, 2024.

Instrument: loan
Principal: $500,000
Counterparty: Juvenescence Limited
Maturity: February 14, 2024
Event: incurrence

Exact text from the filing

On October 3, 2023, AgeX drew $500,000 of its credit available under the Amended and Restated Secured Convertible Promissory Note, as amended, (“Secured Note”) with Juvenescence Limited.

View on SEC.gov

89 debt financings filed in the last 30 days. Browse all debt financings →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-036495

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.